Additive tumor growth inhibition and tumor regression was observed in subcutaneous BC xenograft models expressing both HER3 and HER2 (HER2-amplified and non-amplified), as well as in estrogen receptor-positive and triple-negative BC models [12, 13]. Here, ERBB3 is linked to breast cancer.